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Long-term survival in renal transplant recipients with graft patients with end-stage renal disease (ESRD) [1–4].
function. However, the survival of transplant recipients is signifi-
Background. Death with graft function (DWGF) is a com- cantly lower than age-matched controls in the generalmon cause of graft loss. The risks and determinants of DWGF
population [5, 6]. The relatively higher mortality in renalhave not been studied in a recent cohort of renal transplant
transplant recipients is, in part, due to comorbid medicalrecipients. We performed a population-based survival analysis
of U.S. patients with end-stage renal disease (ESRD) trans- illness, pretransplant dialysis treatment, and factors
planted between 1988 and 1997. uniquely related to transplantation, including immuno-
Methods. Registry data were used to evaluate long-term pa- suppression and other drug effects [7–9]. Studies compar-
tient survival and cause-specific risks of DWGF in 86,502 adult
ing patient survival on dialysis versus renal transplanta-($18 years) renal transplant recipients.
tion often use the intention-to-treat analysis, which, byResults. Out of 18,482 deaths, 38% (N 5 7040) were deaths
with graft function. This accounts for 42.5% of all graft loss. including recipients with graft failure in the transplanted
Patient survival with graft function was 97, 91, and 86% at 1, cohort, does not permit an assessment of the mortality
5, and 10 years, respectively. The risk of DWGF decreased by risk in patients with functioning allografts. Furthermore,
67% (RR 5 0.33, P , 0.001) between 1988 and 1997. The the transplant operation, graft loss, return to dialysis,adjusted rate of DWGF was 4.6, 0.8, 2.2, and 1.4 deaths per
and repeat transplantation are associated with variable1000 person-years for cardiovascular disease, stroke, infections,
time-dependent mortality risks that may not be fullyand malignancy, respectively. The suicide rate was 15.7 versus
9.0 deaths per 100,000 person-years in the general population accounted for when overall post-transplant patient sur-
(P , 0.001). In multivariate analysis, the following factors were vival is studied.
independently and significantly predictive of DWGF: white Death with graft function (DWGF) has been reportedrecipient, age at transplantation, ESRD caused by hyperten-
to occur in 9 to 30% of patients [6, 10–12], thus account-sion or diabetes mellitus, length of pretransplant dialysis, de-
ing for a substantial fraction of graft loss. In most series,layed graft function, acute rejection, panel reactive antibody
.30%, African American donor race, age .45 years, and do- consisting mainly of renal transplantations performed in
nor death caused by cerebrovascular disease. the 1970s to mid-1980s, infection is often reported as
Conclusions. Patients with graft function have a high long- the leading cause of death [13–18]. Risks and causes of
term survival. Although DWGF is a major cause of graft loss,
mortality may have changed because of the more recentthe risk has declined substantially since 1990. Cardiovascular
advances in immunosuppressive protocols, improveddisease was the predominant reported cause of DWGF. Other
causes vary by post-transplant time period. Attention to athero- surgical techniques, and the availability of newer drugs
sclerotic risk factors may be the most important challenge to for the medical treatment of risk factors such as hyper-
further improve the longevity of patients with successful renal tension and hyperlipidemia. Moreover, the transplant
transplants.
population now includes a greater proportion of older
and sicker patients [19, 20]. These developments warrant
It is well established that renal transplantation confers a new assessment of the risks and determinants of mor-
a robust survival advantage over dialysis treatment for tality in the renal transplant population.
The goal of our investigation was to describe the rate
of DWGF and the trends in the risks and causes ofKey words: graft loss, end-stage renal disease, kidney transplant, post-
transplant mortality risks, and renal transplant survival. mortality at different post-transplant intervals in a recent
cohort of U.S. renal transplant recipients. We evaluatedReceived for publication, June 1, 1999
cause-specific mortality rates (in different subgroups)and in revised form August 15, 1999
Accepted for publication August 20, 1999 and the correlations of patient and transplant-related
factors with DWGF in adult renal transplant recipients. 2000 by the International Society of Nephrology
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Table 1. Baseline characteristics of renal transplant recipientsMETHODS
according to vital status
This study used transplant registration and follow-up
Died with Alive withdata collected by the UNOS Scientific Renal Transplant graft function graft function
Registry in combination with ESRD patient data in the Characteristic (N 5 7040) (N 5 58,172) P value
United States Renal Data System (USRDS). After ex- Recipient factors
Age years 49.6612.1 42.8612.4 ,0.001cluding recipients of multiorgan transplants and those
Genderyounger than 18 years of age at transplantation, all pa-
male:female 64.3:35.7 59.5:40.5 ,0.001
tients undergoing renal transplantation between January Race
White 74.8 74.1 0.1841, 1988, and June 30, 1997, were studied. The final study
African American 20.4 19.1 0.014sample consisted of 86,502 patients.
Other 4.8 6.8 ,0.001
Patients were considered to have died with graft func- Primary cause of ESRD
Glomerulonephritis 17.9 25.5 ,0.001tion if: (a) death was not preceded by return to dialysis
Hypertension 17.5 15.4 ,0.001(or refusal to return when indicated) or transplant ne-
Diabetes mellitus 35.6 23.2 ,0.001
phrectomy, (b) no graft failure date or cause of graft Cystic kidney disease 5.8 5.9 0.672
Other 7.7 11.4 ,0.001failure was reported for the index renal transplant, or
Prior renal transplant 10.6 10.8 0.589(c) serum creatinine at the last transplant follow-up visit Donor factors
was less than 4.0 mg/dL. Patients were withdrawn from Living:cadaveric 14.9:85.1 28.5:71.5 ,0.001
Genderthe study (censored) at the first report of graft failure,
male:female 59.0:41.0 57.5:42.5 0.015transplant nephrectomy, resumption of maintenance di- Age years 33.5615.8 33.2615.0 0.144
alysis, retransplantation, or the end of study on June 30, Race
White 87.4 87.5 0.9811998.
African American 10.6 9.8 0.168The cause of death data were obtained from two Other 2.0 2.7 ,0.001
sources: the transplant recipient follow-up form and the Mean serum creatinine
mg/dL 1.960.8 1.760.7 ,0.001ESRD death notification form. Both forms were com-
Abbreviations are: N, number of patients; ESRD, end-stage renal disease.pleted with data from a combination of sources including
Data are % or mean 6 1 sd.
medical records and death certificates. Inconsistencies
between the two forms were resolved in favor of the
ESRD death notification form, except when the cause
of death was missing or unknown in the latter. For the In order to capture any variability in the outcomes
purpose of analysis, the codes for cause of death were across transplant centers (“center effect”) [21–24], we
collapsed into eight categories: cardiovascular deaths, constructed an indicator of the success rate for each
stroke, infection/sepsis, malignant neoplasm, gastroin- center based on the center’s one-year graft survival of
testinal tract disorder, accident/suicide, miscellaneous first cadaveric renal transplants performed in 1995, which
others, and unknown. was then adjusted for the yearly number of transplants
Patient survival with graft function was estimated with per center and the average age of the recipients. A total
the Kaplan-Meier product limit method. Adjusted sur- of 228 centers was divided into three groups according
vival probabilities and cause-specific mortality risks were to the calculated indicator variable (adjusted one-year
computed as days to death using the Cox proportional cadaveric graft survival) in the following way: group I,
hazard regression. Patients were censored (removed) ,85%; group II, 85 to 90%; and group III, .90%. This
from the cause-specific survival analysis at the date of classification scheme included 97, 86, and 45 transplant
death if they died from other causes, therefore being at centers in groups I, II, and III, respectively.
risk of dying of the cause of interest until that time. Statistical analysis performed with SAS software ver-
Chi-square and t-test were used for univariate analysis. sion 6.12 (SAS Institute, Inc., Cary, NC, USA). All tests
Control variables studied in the multivariate patient sur- of statistical significance are two-tailed. A result was con-
vival analysis included recipient age, race, and gender; sidered to be statistically significant if the a was #0.05.
primary cause of ESRD; pretransplant duration of dial-
ysis and pretransplant blood transfusion; cytomegalovi-
RESULTSrus (CMV) status; most recent panel reactive antibody
The study subjects (N 5 86,502) accumulated 345,591(PRA) level; year of transplantation; history of prior
person-years of observation. Table 1 shows the baselinerenal transplantation; delayed graft function (that is,
characteristics of study subjects who were alive and thoseneed for one or more dialysis treatments in the first post-
who died with graft function. Of the 21% (N 5 18,482)transplant week); acute rejection up to six months post-
who died during follow-up, 7040 (38.1%) occurred intransplant; source of donor organ (living vs. cadaveric
donor); donor age, gender, race, and cause of death. patients with graft function. The median time from trans-
Ojo et al: Death with functioning renal graft 309
Table 2. Cause of death with graft function (DWGF) among renal mean age at transplantation of 39 6 12 years compared
transplant recipients, 1988–1997
with 49 6 12 years in other DWGF (P , 0.001). The post-
DWGF (N 5 7040) transplant malignancy accounted for 4.4% of DWGF in
Cause of death N (%) the first year. Thereafter, 12.1 to 13.1% of DWGF were
Cardiovascular 2538 (36.1) due to malignancy.
Stroke 438 (6.2)
To assess whether patient subgroups with differentInfection/sepsis 1240 (17.6)
Malignancy 648 (9.2) causes of ESRD have variable predisposition to death
Gastrointestinal tract disorder 145 (2.1) from specific causes, we analyzed adjusted cause-specific
Accident/suicide 129 (1.8)
mortality rates by cause of ESRD. The mortality rateOther 683 (9.7)
Unknown 1180 (16.8) was overall significantly higher than average for patients
Missing 39 (0.6) with diabetic ESRD (23.7 vs. 15.1 deaths per 1000 per-
son-years, P , 0.001) and lower than average for patients
with cystic kidney disease (9.9 vs. 15.1 deaths per 1000
person-years, P 5 0.007). The excess mortality rates in
plantation to death with function was 23 months (the the diabetic ESRD group were due primarily to more
mean was 30 6 28 months). The most recent mean serum than a twofold higher than average risk of death from
creatinine prior to death was 1.9 6 0.8 mg/dL and was CVD (11.0 vs. 5.0 deaths per 1000 person-years, P ,
less than 2.0 mg/dL in 60% of patients, reflecting good 0.001) and stroke (2.3 vs. 0.9 deaths per 1000 person-
renal allograft function. years, P , 0.001). Post-transplant lymphoproliferative
The causes of DWGF are summarized in Table 2. disease (PTLD) accounted for 13.4% (N 5 87) of deaths
Cardiovascular disease (CVD) was the leading cause of caused by malignancy.
DWGF (36.1%, N 5 2538). Half of these cardiovascular The unadjusted overall patient survival with graft
deaths occurred following acute myocardial infarction function was 97, 91, and 86% at 1, 5, and 10 years,
(N 5 1274). Infection/sepsis and malignancy were the respectively. The 10-year survival with graft function in
second and third leading causes of death, respectively. patients with ESRD caused by glomerulonephritis was
Miscellaneous causes, including pulmonary embolism, 88%, other causes 87%, cystic kidney disease 85%, hy-
chronic obstructive pulmonary disease, hemorrhage from pertension 81%, and diabetes mellitus 76%. Overall,
ruptured vascular aneurysm or other sites, dementia, and patients with ESRD caused by cystic kidney disease had
diabetic coma, accounted for 9.7% of DWGF. The cause a lower than average rate of DWGF (14.4 vs. 21.0 deaths
of DWGF was unknown in 16.8% and missing (that is, per 1000 person-years, P 5 0.001) but a significantly
not reported) in 0.6% of deaths. higher rate of DWGF from malignancy (1.9 vs. 1.4 deaths
Overall, DWGF accounted for 42.5% of all graft loss, per 1000 person-years; P 5 0.05) and stroke (1.5 vs. 0.9
with the proportion increasing from 27.2% during the deaths per 1000 person-years, P 5 0.001).
first-month post-transplant to 47.3% between post-trans- Multivariate Cox proportional hazard regression was
plant months 2 and 12, and then decreasing to 43.2% used to identify factors predisposing to DWGF. Table 3
during months 13 through 60, and 39.9% between post- shows the adjusted risk ratio (RR) and the corresponding
transplant months 61 and 120. Almost half (47.1%) of significance level of patient- and transplant-related fac-
the DWGF occurring within 30 days after transplantation tors associated with DWGF during the first 120 months
was due to CVD, primarily acute myocardial infarction. after transplantation. As would be expected, the age
Ischemic heart disease remained as the leading cause in at transplantation exerted the strongest effect on the
each of the post-transplant intervals under study. Infec- probability of being alive with graft function. Compared
tion was the second leading cause of DWGF, reaching with age 18 to 29 years, recipients older than 65 years
the highest level of 28.2% during the 2- to 12-month at transplantation were seven times more likely to die
interval; however, the frequency of infectious deaths was with function (RR 5 7.02, P , 0.001). The risk of DWGF
markedly lower (less than 15% of deaths) during all and recipient age also followed a highly significant direct
other intervals. There were 62 deaths from suicide and relationship for the intermediate age groups (years) 30
71 deaths from accidents. Only two of the accidental to 44 (RR 5 1.76), 45 to 54 (RR 5 3.08), and 55 to 64
deaths were reported as transplant related. The rate of (RR 5 4.64). Using glomerulonephritis as a reference
suicide was 15.7 deaths per 100,000 person-years com- group (RR 5 1.00), patients with ESRD caused by cystic
pared with 9 deaths per 100,000 patient-years in the kidney disease were at a lower risk of DWGF (RR 5
United States general population (P 5 0.0001) [25]. The 0.81, P , 0.001), but diabetes mellitus (RR 5 1.93, P ,
risk of suicide was highest between 13 and 60 months 0.001) and hypertension (RR 5 1.12, P 5 0.003) were
post-transplant. The median time from transplantation associated with a greater risk of DWGF.
to suicide was 16 months versus 23 months for all DWGF After controlling for other factors, the risk of DWGF
was lower in both African American and other race(P , 0.001). The victims of suicide were younger with
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Variable (reference) riska interval P value
Age at transplantation
(18–29 years)
30–44 years 1.76 1.54–1.95 ,0.001
45–54 years 3.08 2.77–3.42 ,0.001
55–64 years 4.64 4.18–5.17 ,0.001
$65 years 7.02 6.21–7.94 ,0.001
Male recipient (female) 1.16 1.11–1.22 ,0.001
Recipient race (white) 1.00
African American 0.92 0.86–0.98 0.009
Other 0.76 0.68–0.85 ,0.001
Primary cause of ESRD
(glomerulonephritis)
Diabetes mellitus 1.93 1.82–2.05 ,0.001
Fig. 1. Trends in the risk of death with graft function: 1988–1997Hypertension 1.12 1.04–1.20 0.003
(N 5 86,502).Cystic kidney disease 0.81 0.73–0.90 ,0.001
Other 0.94 0.85–1.03 0.175
Repeat transplant (primary
transplant) 1.06 0.97–1.15 0.201
Transplant era (1988–1992) of dialysis therapy. Compared with preemptive renal
1993–1997 0.69 0.65–0.73 ,0.001
transplantation, the risk of DWGF increased with thePretransplant transfusion 1.10 1.06–1.17 ,0.001
(none) duration of pretransplant dialysis treatment from an ad-
Prior dialysis (preemptive justed RR of 1. 14 for 7 to 12 months of dialysis treatmenttransplant)
to 1.41 for more than 24 months of treatment.1–6 months 1.00 0.89–1.11 0.945
7–12 months 1.14 1.03–1.25 0.009 A number of donor factors and early transplant events
13–24 months 1.20 1.10–1.31 ,0.001 were significantly associated with greater probability of.24 months 1.41 1.29–1.54 ,0.001
DWGF. These included delayed graft function, acuteCadaveric donor (living donor) 1.19 0.89–1.30 0.376
Delayed graft function (no) 1.28 1.21–1.36 ,0.001 rejection episode during the first six months, African
Early acute rejection (no) 1.12 1.06–1.18 ,0.001
American donor race, donor age above 45 years, andPretransplant PRA (0%)
21–10% 1.02 0.96–1.09 0.449 donor death because of cerebrovascular disease as com-
11–30% 1.00 0.90–1.10 0.944 pared with head trauma.
.30% 1.18 1.08–1.30 ,0.001
The risk of DWGF was substantially lower for trans-Donor race (white)
African American 1.11 1.02–1.20 0.014 plants performed after 1990. When each year of trans-
Other 0.91 0.76–1.08 0.275 plantation was entered separately into the Cox model
Donor age (19–29 years)
along with all other covariates, there was a clear trend0–6 years 1.05 0.90–1.22 0.522
7–11 years 1.10 0.96–1.27 0.175 toward improved survival for each year after 1988 (refer-
12–18 years 1.02 0.94–1.10 0.617 ence), which reached statistical significance after 198930–44 years 1.02 0.95–1.09 0.634
(Fig. 1). From 1990, the reduction in risk continued until45–64 years 1.09 1.02–1.18 0.016
Male donor (female) 0.97 0.92–1.02 0.169 the most recent year of the study (1997). The RR of
Donor cause of death (head DWGF in patients grafted in 1997 was 67% lower thantrauma)
in patients transplanted in 1988 (RR 5 0.33, P , 0.001).Cerebrovascular disease 1.09 1.02–1.17 0.017
Transplant center (group III) In the final model reported in Table 3, transplants were
Group I 1.26 1.17–1.35 ,0.001 divided into two eras (1988 through 1992 vs. 1993 throughGroup II 1.22 1.13–1.30 ,0.001
1997) to show an overall 31% reduction in the risk ofa Adjusted for all factors listed in this table
DWGF for patients undergoing renal transplantation be-
tween 1993 and 1997 compared with the earlier years.
The reduction in the risk of DWGF between the eras
was evident for all causes of death examined, being great-group recipients compared with whites (RR 5 0.92, P 5
0.009 for African Americans, and RR 5 0.76, P , 0.001 est for infectious deaths, which declined by 23% in the
more recent time period (1993 through 1997, RR 5 0.768,for others). Other recipient factors associated with
DWGF were male gender (RR 5 1.16, P , 0.001), blood P , 0.001) compared with 1988 through 1992.
Finally, we found differences in the risk of DWGFtransfusion (RR 5 1.10, P , 0.001), and presensitization
with most recent PRA level greater than 30% (RR 5 among transplant centers in a pattern consistent with the
well-documented center-dependent variability in graft1.18, P , 0.001). DWGF was less likely to occur if trans-
plantation was preceded by no or less than six months survival [21–24]. In center groups I, II, and III (classified
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according to one-year cadaveric graft survival of ,85%, have uniformly reported CVD as the most important
cause of mortality [6, 11, 12].85 to 90%, and .90%, respectively), the risk of DWGF
increased inversely with graft survival. Using center The suicide rate in this study was higher than that
reported in the U.S. general population. A high rategroup III as the reference group, the RR of DWGF in
center groups I and II was 1.26 and 1.22, respectively of suicide has been reported in transplant patients, but
mostly in the setting of graft failure occurring early after(P , 0.001 each). Center size did influence the risk of
DWGF. Center group I with the lowest patient and graft transplantation [18]. ESRD is associated with devasta-
ting psychological trauma and high potential for situa-survival had a higher proportion of African American
recipients (27.3%) compared with 19.3 and 19.5% in tional depression [34–37]. The relatively high rate of sui-
cide observed in patients who have been freed from thecenter groups II and III, respectively (P 5 0.001).
tedium of chronic dialysis treatment (for which higher
suicide rates have been reported) illustrates the ongoing
DISCUSSION
psychological burden attendant to ESRD as a chronic
The results of this observational study show a marked disease [20, 38]. In the present study, suicide was more
and significant improvement over time in the survival of likely in younger recipients, and unlike in the general
renal transplant recipients with functioning grafts. The population, there was no racial or gender predisposition.
10-year patient survival with function increased from 55 Although 35% of suicides occurred in the first 12
to 60% in the late 1970s [14, 16, 26–29] to 86% in this months post-transplant, the median time from transplan-
series. Importantly, the post-transplant mortality rate tation to suicide was 16 months. This indicates that mood
continued to decline despite a substantial increase in the disturbance associated with high-dose corticosteroid ther-
number of high-risk ESRD patients undergoing renal apy in the immediate post-transplant period was unlikely
transplantation [19, 20]. to be the major proximate cause of suicide. Even after
The study also highlights the importance of DWGF successful transplantation, emotional crisis may be precipi-
relative to other competing risks of graft loss. Almost tated by abrupt termination of social support provided
half (43%) of all graft loss was due to death with function, by the in-center dialysis programs or the inability to
and the effect of DWGF on graft loss was gradually realize the anticipated dramatic change in life necessary
more pronounced with longer time since transplantation. to sustain an independent mode of living [39]. The poten-
This finding supports the strong case previously made tial for suicide may also be heightened by treatment of
by others [11, 12] that graft survival analyses should concurrent medical conditions, for example, as a de-
consider death with function for better interpretation. pressive side-effect of antihypertensive medications [40].
This is particularly important as graft survival statistics In line with other studies [6, 9, 10], the most important
are increasingly being used to evaluate programs and determinants of death with function were recipient age
formulate policy [30]. and ESRD caused by diabetes mellitus. The direct rela-
The hazard of mortality from CVD was most pro- tionship between recipient age and mortality risk in all
nounced in diabetics in whom the adjusted CVD death age groups under study is in agreement with a previous
rate was twofold higher than any other group. Primary report [10]. The excess risk of death in diabetics can
acute ischemic heart disease accounted for most of the be explained, primarily, by significantly higher mortality
cardiovascular deaths and was predominant during all rates from both CVD and stroke. ESRD from cystic
post-transplant intervals. This is in agreement with sev- kidney disease conferred an overall lower risk of death,
eral reports [11, 16, 17, 29], including a series reported but the slightly higher risk specifically for stroke and
by Lindholm et al in which ischemic heart disease was malignancy-related deaths in this subgroup may be re-
the overwhelming cause of death, accounting for 53% lated to the association between polycystic kidney dis-
of deaths with graft function [6]. However, many more ease and cerebral aneurysm and renal cancer. As recently
studies, consisting mainly of earlier series, have reported shown by Cosio et al, we also found prior history and
infection as the leading cause of death in a mix of trans- duration of pretransplant dialysis treatment (.6 months)
plant recipients with and without graft function [13–15, to be associated with an increased risk of death with
18, 26–28, 31–33]. The discrepancy in the leading cause function [9]. This finding suggests longer exposure to
of death among studies can be explained by several dif- the immunosuppressive effect of both renal failure and
ferences, including the transplant era (1970s to early dialysis and greater likelihood of malnutrition, both of
1980s vs. more recent years), patient selection, post- which may adversely affect post-transplant survival [9].
transplant interval under study, nosological definition of In line with other studies [6, 10, 16], increased mortal-
terms, and the source of mortality statistics. In contrast ity was associated with established risk factors for graft
to others [16, 29, 32], we estimated survival from the date survival such as presensitization, delayed graft function,
of transplantation to avoid bias of survivorship effects in acute rejection, advanced donor age, and donor death
caused by cerebrovascular disease. In some cases, thisprevalent cohorts, and studies using a similar approach
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concordance of risk factors for mortality and graft sur- factors limits the interpretations of the results, particu-
larly given the dominance of cardiovascular deaths invival suggests a direct mechanistic relationship. For ex-
ample, atherosclerotic disease with iliofemoral invol- the study cohort.
In summary, the survival of patients with functioningvement is prevalent in the renal transplant population
[41] and may predispose to DWGF followed by success- renal transplants is high and has markedly improved in
recent years. CVD, primarily acute myocardial infarc-ful graft recovery and subsequent premature cardiovas-
cular death. Alternatively, risk factors such as plasma tion, supersedes infection as the leading cause of death
at all times during the first 10 years following renal trans-renin activity (PRA) levels may carry over to DWGF as
an epiphenomenon of the mix of patients selected for plantation. Cause-specific mortality varies substantially
depending on the post-transplant interval under study.transplantation. In the latter respect, the presence of a
“center effect” in patient survival suggests differences Mental health support should be an integral part of post-
transplant care because emotional dehiscence may be-in the mix of transplant candidates and management of
post-transplant complications between centers. Al- come a lethal complication despite successful renal trans-
plantation, particularly in younger recipients. Recipientthough the cause of center variability has not been fully
elucidated, clinical differences not measurable in registry age and ESRD caused by diabetes mellitus were the
overriding determinants of DWGF. Preemptive and liv-data have been implicated [21].
Serum creatinine (SCr) at the last follow-up was used ing-donor renal transplantation independently favor im-
proved longevity. Attention to cardiovascular risk fac-to define patients dying with graft function. However,
SCr was recorded only semiannually during the first year tors, particularly in diabetics, offers the greatest potential
to improve the chances of living longer with graft func-and annually thereafter. Thus, whether patients in the
study actually died with graft function as opposed to tion.
death because of impairment of graft function is open
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